Euglycemic Diabetic Ketoacidosis with Persistent Diuresis Treated with Canagliflozin

被引：13

作者：

Adachi, Junichiro ^{[1
]}

Inaba, Yuusuke ^{[1
]}

Maki, Chisato ^{[1
]}

机构：

[1] Ohkubo Hosp, Dept Internal Med, Tokyo, Japan

来源：

INTERNAL MEDICINE | 2017年 / 56卷 / 02期

关键词：

sodium-glucose cotransporter 2 inhibitors; euglycemic diabetic ketoacidosis; DOUBLE-BLIND; DAPAGLIFLOZIN;

D O I：

10.2169/internalmedicine.56.7501

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Diabetic ketoacidosis is characterized by hyperglycemia, anion-gap acidosis, and increased plasma ketones. After the resolution of hyperglycemia, persistent diuresis is rare. We herein report the case of a 27-year-old Asian woman with type 2 diabetes who was treated with a sodium-glucose cotransporter 2 (SGLT2) inhibitor (canagliflozin) who developed euglycemic diabetic ketoacidosis and persistent diuresis in the absence of hyperglycemia. Physicians should consider euglycemic diabetic ketoacidosis in the differential diagnosis of patients treated with SGLT2 inhibitors.

引用

收藏

页码：187 / 190

页数：4

相关论文

共 15 条

[1]

[Anonymous], 2015, FDA Drug Safety Communication: FDA warns that SGLT2 inhibitors for diabetes may result in a serious condition of too much acid in the blood

[2]

Burr K, 2015, END SOC ANN M EXP 20

[3] Diabetic Ketoacidosis and Related Events in the Canagliflozin Type 2 Diabetes Clinical Program [J].

Erondu, Ngozi ;

Desai, Mehul ;

Ways, Kirk ;

Meininger, Gary .

DIABETES CARE, 2015, 38 (09) :1680-1686

[4] Case of ketoacidosis by a sodium-glucose cotransporter 2 inhibitor in a diabetic patient with a low-carbohydrate diet [J].

Hayami, Tomohide ;

Kato, Yoshiro ;

Kamiya, Hideki ;

Kondo, Masaki ;

Naito, Ena ;

Sugiura, Yukako ;

Kojima, Chika ;

Sato, Sami ;

Yamada, Yuichiro ;

Kasagi, Rina ;

Ando, Toshihito ;

Noda, Saeko ;

Nakai, Hiromi ;

Takada, Eriko ;

Asano, Emi ;

Motegi, Mikio ;

Watarai, Atsuko ;

Kato, Koichi ;

Nakamura, Jiro .

JOURNAL OF DIABETES INVESTIGATION, 2015, 6 (05) :587-590

[5] Exploring the Potential of the SGLT2 Inhibitor Dapagliflozin in Type 1 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Pilot Study [J].

Henry, Robert R. ;

Rosenstock, Julio ;

Edelman, Steven ;

Mudaliar, Sunder ;

Chalamandaris, Alexandros-Georgios ;

Kasichayanula, Sreeneeranj ;

Bogle, Allyson ;

Iqbal, Nayyar ;

List, James ;

Griffen, Steven C. .

DIABETES CARE, 2015, 38 (03) :412-419

[6] SGLT inhibition and euglycaemic diabetic ketoacidosis [J].

Hine, Julia ;

Paterson, Heather ;

Abrol, Esha ;

Russell-Jones, David ;

Herring, Roselle .

LANCET DIABETES & ENDOCRINOLOGY, 2015, 3 (07) :503-504

[7] Hyperglycemic Crises in Adult Patients with Diabetes [J].

Kitabchi, Abbas E. ;

Umpierrez, Guillermo E. ;

Miles, John M. ;

Fisher, Joseph N. .

DIABETES CARE, 2009, 32 (07) :1335-1343

[8] Randomized, Double-Blind Trial of Triple Therapy With Saxagliptin Add-on to Dapagliflozin Plus Metformin in Patients With Type 2 Diabetes [J].

Matthaei, Stephan ;

Catrinoiu, Doina ;

Celinski, Aleksander ;

Ekholm, Ella ;

Cook, William ;

Hirshberg, Boaz ;

Chen, Hungta ;

Iqbal, Nayyar ;

Hansen, Lars .

DIABETES CARE, 2015, 38 (11) :2018-2024

[9] EUGLYCEMIC DIABETIC KETOACIDOSIS [J].

MUNRO, JF ;

CAMPBELL, IW ;

MCCUISH, AC ;

DUNCAN, LJP .

BRITISH MEDICAL JOURNAL, 1973, 2 (5866) :578-580

[10] Euglycemic Diabetic Ketoacidosis: A Potential Complication of Treatment With Sodium-Glucose Cotransporter 2 Inhibition [J].

Peters, Anne L. ;

Buschur, Elizabeth O. ;

Buse, John B. ;

Cohan, Pejman ;

Diner, Jamie C. ;

Hirsch, Irl B. .

DIABETES CARE, 2015, 38 (09) :1687-1693